MRP-1/CD9,KAI1/CD82, andME491/CD63, have been reported to be associated with the metastatic potential of solid tumors. The aim of this study was to determine whether their expression in tumor tissues is a useful indicator for prognosis in breast cancer patients. We studied 109 breast cancer patients who underwent surgery. Quantitative reverse transcription-polymerase chain reaction analysis was performed to evaluate the expression of these genes. The results were confirmed with immunohistochemistry. All of the carcinomas wereME491/CD63 positive. Thirty-six tumors wereMRP-1/CD9 negative. The disease-free survival rate and the 5-year survival rate of patients withMRP-1/CD9-negative tumors were both significantly lower than that in patients with MRP-1/CD9-positive tumors (P = 0.0005 and P = 0.0380, respectively). Sixty-five tumors wereKAI1/CD82 negative. The disease-free survival rate of patients with KAI1/CD82-negative tumors was significantly lower than that of patients withKAI1/CD82-positive tumors (P = 0.0065). Cox regression analysis demonstrated thatMRP-1/CD9 status (P = 0.0016) andKAI1/CD82 status (P = 0.0234) were useful indicators for the disease-free survival of breast cancer patients. The disease-free survival rate and 5-year survival rate of patients with either MRP-1/CD9-negative orKAI1/CD82-negative tumors were both significantly lower than patients who were positive for both genes (P = 0.0003 and P = 0.0292, respectively). The expression of MRP-1/CD9 and KAI1/CD82genes are useful indicators of a poor prognosis in breast cancer patients.
Cited by (0)
Supported in part by Grants-in-Aid from the Ministry of Education, Science and Culture of Japan (No 07557253 and 08407040) to M. Miyake.
